Word count: 1203
Main Text
Acute promyelocytic leukemia (APL) occurs in about 5-30% of adult de novo AML and is characterized by the presence of the chromosomal translocation t(15;17)(q24;q21). The resulting PML-RARA chimeric gene involves the retinoic acid receptor alpha-(RARA) gene on chromosome 17 and the PML gene, a putative transcription factor, on chromosome 15.
The resulting PML-RARA chimeric protein is crucial to the pathogenesis of APL as it is thought to contribute two oncogenic hits in one: the block of differentiation and the aberrant self-renewal of APL cells. 1 Since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) for the treatment of APL, the overall survival rate has improved dramatically.
2;3 However, relapse/refractory patients showing resistance to ATRA and/or ATO are recognized still as a clinically significant problem. It is likely that concurrent genetic aberrations at initial diagnosis predispose patients to relapse or that additional genetic lesions acquired during the course of APL lead to treatment resistance. 4 Genetic mutations resulting in amino acid substitution in the RARA ligand binding domain (LBD)
and the PML-B2 domain of PML-RARA, respectively, have been reported as molecular mechanisms underlying resistance to ATRA and ATO. In the presence of LBD mutation, binding of ATRA to LBD is generally impaired, and ligand-dependent co-repressor dissociation and degradation of PML-RARA by the proteasome pathway, leading to cell differentiation, are inhibited.
; 8
Mutations in the PML-B2 domain affect direct binding of ATO with PML-B2, and PML-RARA SUMOylation with ATO followed by multimerization and degradation is impaired.
The aim of the study was to evaluate the mutational spectrum of APL both at initial diagnosis and relapse and identify potential genetic defects leading to treatment resistance.
We analyzed a cohort of 123 adult de novo APL cases including 14 cases who showed hematologic or molecular relapse. Patient characteristics are given in at the time point of second relapse 64 months after initial diagnosis and treatment with ATRA and ATO. No sample of first relapse was available in our laboratory, so it is unclear, whether the PML B2 domain mutation was already detectable at this time point.
In conclusion, in our cohort of 123 adult de novo APL cases, 67% carry additional molecular mutations, with the most frequent additional molecular mutation being FLT3-ITD (41%)
followed by FLT3-TKD mutations (12%) and mutations in WT1 (10%). In 57% of relapsed APL, the molecular mutation pattern changed but no clear driver gene/genes predicting relapse could be identified in the present study. Acquired mutations within the PML-RARA fusion transcript were detected in 29% of relapsed APL patients and may account for an impaired response to therapy. 
Supplementary methods:
Evaluation of variants:
For the evalauation of variants, the following databases were used: COSMIC a. mutation
• Truncating variants (nonsense mutations, essential splice mutations or frameshift indel) in genes implicated in myeloid malignancies
• Missense/inframe variants with VAF <30%
• Known oncogenic variants previously reported in the literature and/or in the above mentioned databases b. VUS
• Variants identified outside functional domains
• Variants with VAF >30%
• Variants not previously reported in the literature and/or in the above mentioned databases
Variants defined as VUS were not considered in the present study.
